BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23720365)

  • 1. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Comtet L; Lövgren Bengtsson K; Pringle J; Zientara S; Valarcher JF
    Clin Vaccine Immunol; 2013 Aug; 20(8):1115-22. PubMed ID: 23720365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.
    Anderson J; Bréard E; Lövgren Bengtsson K; Grönvik KO; Zientara S; Valarcher JF; Hägglund S
    Clin Vaccine Immunol; 2014 Mar; 21(3):443-52. PubMed ID: 24451327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
    Utrilla-Trigo S; Jiménez-Cabello L; Calvo-Pinilla E; Marín-López A; Lorenzo G; Sánchez-Cordón P; Moreno S; Benavides J; Gilbert S; Nogales A; Ortego J
    J Virol; 2022 Feb; 96(3):e0161421. PubMed ID: 34787454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.
    Bartram DJ; Heasman L; Batten CA; Oura CA; Plana-Durán J; Yuen HM; Wylie AD
    Vet J; 2011 May; 188(2):193-6. PubMed ID: 20466568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice.
    Legisa DM; Perez Aguirreburualde MS; Gonzalez FN; Marin-Lopez A; Ruiz V; Wigdorovitz A; Martinez-Escribano JA; Ortego J; Dus Santos MJ
    Vaccine; 2015 May; 33(22):2614-9. PubMed ID: 25858859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.
    Celma CC; Boyce M; van Rijn PA; Eschbaumer M; Wernike K; Hoffmann B; Beer M; Haegeman A; De Clercq K; Roy P
    J Virol; 2013 Sep; 87(17):9856-64. PubMed ID: 23824810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine.
    Moulin V; Noordegraaf CV; Makoschey B; van der Sluijs M; Veronesi E; Darpel K; Mertens PP; de Smit H
    Vaccine; 2012 Mar; 30(12):2228-35. PubMed ID: 22207091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.
    van Gennip RG; van de Water SG; Maris-Veldhuis M; van Rijn PA
    PLoS One; 2012; 7(9):e44619. PubMed ID: 23049753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
    Barros SC; Cruz B; Luís TM; Ramos F; Fagulha T; Duarte M; Henriques M; Fevereiro M
    Vet Microbiol; 2009 Jun; 137(3-4):252-9. PubMed ID: 19233575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTV antibody longevity in cattle five to eight years post BTV-8 vaccination.
    Ries C; Beer M; Hoffmann B
    Vaccine; 2019 May; 37(20):2656-2660. PubMed ID: 30979569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle.
    Savini G; Hamers C; Conte A; Migliaccio P; Bonfini B; Teodori L; Di Ventura M; Hudelet P; Schumacher C; Caporale V
    Vet Microbiol; 2009 Jan; 133(1-2):1-8. PubMed ID: 18617335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
    Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
    Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.